(-0.01%) 5 477.75 points
(-0.02%) 38 810 points
(0.02%) 19 925 points
(0.26%) $80.54
(1.22%) $2.82
(0.12%) $2 331.70
(-0.34%) $29.29
(-0.09%) $970.00
(0.02%) $0.932
(-0.15%) $10.64
(0.07%) $0.788
(-1.86%) $86.81
@ $61.71
Išleistas: 17 birž. 2024 @ 21:55
Grąža: 0.12%
Ankstesnis signalas: birž. 17 - 20:59
Ankstesnis signalas:
Grąža: -0.34 %
Live Chart Being Loaded With Signals
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform...
Stats | |
---|---|
Šios dienos apimtis | 1.22M |
Vidutinė apimtis | 1.31M |
Rinkos kapitalizacija | 5.25B |
EPS | $-1.430 ( Q1 | 2024-05-08 ) |
Kita pelno data | ( $-1.370 ) 2024-08-05 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-22.88 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $1.750 (2.83%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-30 | George Simeon | Buy | 13 000 | Stock Option (Right to buy) |
2024-05-30 | Behbahani Ali | Buy | 13 000 | Stock Option (Right to buy) |
2024-05-30 | Mahatme Sandesh | Buy | 13 000 | Stock Option (Right to Buy) |
2024-05-30 | Fardis Maria | Buy | 13 000 | Stock Option (Right to Buy) |
2024-05-30 | Rommel Christian | Buy | 26 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
59.81 |
Last 97 transactions |
Buy: 2 080 741 | Sell: 522 501 |
Tūris Koreliacija
CRISPR Therapeutics AG Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
OZEM | 1 |
DECAU | 0.95 |
AGBAW | 0.939 |
ARVN | 0.927 |
REE | 0.917 |
CALC | 0.91 |
WSC | 0.899 |
GTACW | 0.899 |
GANX | 0.895 |
NUVL | 0.89 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
INTJ | -0.917 |
HTZWW | -0.904 |
FUFUW | -0.898 |
ECBK | -0.896 |
GBLMX | -0.895 |
SENEA | -0.882 |
KYTX | -0.879 |
ADNWW | -0.879 |
NTRP | -0.876 |
SHLT | -0.872 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
CRISPR Therapeutics AG Koreliacija - Valiuta/Žaliavos
CRISPR Therapeutics AG Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $370.00M |
Bruto pelnas: | $239.75M (64.80 %) |
EPS: | $-1.940 |
FY | 2023 |
Pajamos: | $370.00M |
Bruto pelnas: | $239.75M (64.80 %) |
EPS: | $-1.940 |
FY | 2022 |
Pajamos: | $436 000 |
Bruto pelnas: | $-109.81M (-25 186.70 %) |
EPS: | $-8.36 |
FY | 2021 |
Pajamos: | $914.96M |
Bruto pelnas: | $914.96M (100.00 %) |
EPS: | $4.97 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.